Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashkan Emadi

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Pharmacogenomics|August 28, 2012
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaAshkan Emadi, Judith E Karp
Expert Review of Anticancer Therapy|December 25, 2008
Anagrelide: 20 years laterAshkan Emadi, Jerry L Spivak
American Journal of Hematology|August 26, 2009
Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuriaAshkan Emadi, Robert A Brodsky
Journal of the National Cancer Institute|October 24, 2017
Breaking Mitochondrial Fasting for Cancer Treatment: Old Wine in New BottlesAshkan Emadi, Rena G Lapidus
Leukemia & Lymphoma|September 13, 2012
CD30 in myeloid malignancies: hitting the bull's-eye with an available dartAshkan Emadi, Judith E Karp
American Journal of Leukemia Research|December 7, 2020
High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemiaCiera L Patzke, Ashkan Emadi
Blood Reviews|May 18, 2010
Arsenic trioxide - An old drug rediscoveredAshkan Emadi, Steven D Gore
Archives of Iranian Medicine|November 4, 2014
PhotoclinicMichael J Nathenson, Ashkan Emadi
Leukemia & Lymphoma|March 1, 2014
The state of the union on treatment of acute myeloid leukemiaAshkan Emadi, Judith E Karp
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 23, 2019
Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemiaMacKenzie Crist, Ashkan Emadi, Alison Duffy
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Pharmacogenomics|August 28, 2012
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaAshkan Emadi, Judith E Karp
Expert Review of Anticancer Therapy|December 25, 2008
Anagrelide: 20 years laterAshkan Emadi, Jerry L Spivak
American Journal of Hematology|August 26, 2009
Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuriaAshkan Emadi, Robert A Brodsky
Journal of the National Cancer Institute|October 24, 2017
Breaking Mitochondrial Fasting for Cancer Treatment: Old Wine in New BottlesAshkan Emadi, Rena G Lapidus
Leukemia & Lymphoma|September 13, 2012
CD30 in myeloid malignancies: hitting the bull's-eye with an available dartAshkan Emadi, Judith E Karp
American Journal of Leukemia Research|December 7, 2020
High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemiaCiera L Patzke, Ashkan Emadi
Blood Reviews|May 18, 2010
Arsenic trioxide - An old drug rediscoveredAshkan Emadi, Steven D Gore
Archives of Iranian Medicine|November 4, 2014
PhotoclinicMichael J Nathenson, Ashkan Emadi
Leukemia & Lymphoma|March 1, 2014
The state of the union on treatment of acute myeloid leukemiaAshkan Emadi, Judith E Karp
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 23, 2019
Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemiaMacKenzie Crist, Ashkan Emadi, Alison Duffy
Pageof 12